Megakaryon was founded in 2011 aiming at the clinical application of platelets produced by megakaryocytes derived from human iPS cells. It owns intellectual property of immortalizing and storing frozen megakaryocytes derived from human iPS cells. In August 2017, the company formed a consortium from 13 companies towards commercialization of this technology for transfusion blood products. Members of the consortium are Otsuka Pharmaceuticals, Sysmex and others.
Source: Megakaryon news release, December 25, 2017
Request a quote for deeper information from